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Pernelle Lavaud1 and Fabrice Andre1,2*Abstract
Breast cancers over-express the human epidermal growth factor receptor 2 (HER2) in about 15% of patients. This
transmembrane tyrosine kinase receptor activates downstream signaling pathways and leads to proliferation of cancer
cells. Trastuzumab, an anti-HER2 monoclonal antibody, improves outcome in women with early and metastatic breast
cancer. Resistance to trastuzumab involves the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR)
pathway, truncation of the Her2 receptor or lack of immune response. The last decade has seen major advances in
strategies to overcome resistance to trastuzumab. This includes the development of antibody-drug conjugates, dual
HER2 inhibition strategies, inhibition of PI3K/mTOR pathway and development of modulators of immune checkpoints.
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About 15% of breast cancer over-expresses the human
epidermal growth factor receptor 2 (HER2) [1,2]. HER2
is a transmembrane tyrosine kinase receptor that is a
member of the human epidermal growth factor receptor
(EGFR/HER) family. This receptor is involved in prolif-
eration and survival of epithelial cells. Activation of
HER2 generates activation of downstream signaling
pathways including mitogen-activated protein kinase
(MAPK) and phosphoinositide 3-kinase (PI3K/Akt) [3].
Over-expression of HER2 predicts poorer prognosis [4,5]
and higher sensitivity to chemotherapy, such as anthracy-
cline and paclitaxel [5,6]. On the opposite side, HER2
overexpression has been associated with resistance to
tamoxifen [6-9]. Finally, HER2 positive breast cancer is as-
sociated with an increased risk of brain metastases [10].
Trastuzumab is a humanized recombinant monoclonal
antibody that targets the HER2 extracellular domain.
The use of trastuzumab is considered as standard of care
both in early and metastatic HER2 over-expressing breast
cancer. Numerous clinical trials have confirmed that tras-
tuzumab improves overall survival (OS) in metastatic* Correspondence: Fabrice.ANDRE@gustaveroussy.fr
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article, unless otherwise stated.breast cancers [11-13]. In early breast cancers, it improves
disease free survival (DFS) and OS [14-16] and increases
pathological complete response (pCR) in a neoadjuvant
setting when combined with chemotherapy (66.7% with
trastuzumab versus 25% without) [14,17,18].
Its antitumor activity is hypothesized to be related to
two different mechanisms of action: downregulation of the
intracellular signaling pathway via the PI3K and MAPK
pathways, and activation of the immune response via anti-
body dependent cell-mediated cytotoxicity (ADCC) and
eventually adaptive immune response [19-22].
Unfortunately, resistances to trastuzumab occur, mainly
in the metastatic setting, where most of the patients treated
with trastuzumab have a disease progression within one
year [23]. Molecular mechanisms of trastuzumab resistance
may involve signaling from other HER receptors, such as
HER3 or epidermal growth factor receptor (EGFR) [24],
insulin-like growth factor receptor [25,26], activation of
PI3K/AKT/mTOR [27], overexpression of c-MET [28] or
loss of PTEN (phosphatase and TENsin homolog) [27,29],
up-regulation of src activity [30] or MUC4 [31,32],
increased VEGF (vascular endothelial growth factor)
expression [33], expression of the p95 isoform of HER2
[34] and co-expression of EGFR [35].
In the present review, we will present clinical data on
the main strategies that aimed at overcoming trastuzumabentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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are reported in Figure 1. The results of the main random-
ized trials are summarized in Table 1.
Small tyrosine kinase inhibitors: Lapatinib and neratinib
Lapatinib
Lapatinib is a small molecule, dual tyrosine kinase inhibi-
tor (TKI) of EGFR and HER2. It inhibits the intracellular
kinase domain of HER2 contrary to trastuzumab that in-
hibits the extracellular domain and blocks ligand-induced
heterodimer signaling. It could prevent signaling related
to truncated HER2 receptor or enhance trastuzumab-
dependant ADCC, thanks to an accumulation of HER2 at
the cell surface.
It has shown its efficacy when combined with capecit-
abine, in terms of time to progression (hazard ratio
(HR): 0.57; 95% confidence interval (CI) 0.43 to 0.77;
P <0.001). In the same trial, the median overall survival
times were 75 weeks for the combination arm and
64.7 weeks for the capecitabine arm (HR 0.87; 95% CI
0.71 to 1.08; P = 0.210) [36-38]. Lapatinib has also shown
its efficacy in terms of OS, when combined with paclitaxel,
over paclitaxel single agent (HR 0.74; 95% CI 0.58 to 0.94;
P = 0.0124) [39].
The efficacy of dual HER2 blockade with trastuzumab
and lapatinib was investigated in the phase III study
EGF104900. Patients with HER2-positive metastatic breast
cancer (MBC) who progressed during trastuzumab treat-
ment were randomly assigned to receive lapatinib in mono-


















Figure 1 HER2-directed drugs and targets; mechanisms of action.combination was associated with better outcome both
in progression free survival (PFS) (HR 0.74; 95% CI 0.58
to 0.94; P = 0.011) and OS (HR 0.74; 95% CI 0.57 to
0.97; P = 0.026) [40].
Following the results of these randomized trials in the
metastatic setting, the efficacy of lapatinib has been
investigated in early breast cancer, mainly in the context
of trials testing dual inhibition of HER2. In the phase III
trial of NSABP (protocol B-41), 529 patients were ran-
domized to receive weekly paclitaxel with either trastuzu-
mab weekly, lapatinib daily or the association trastuzumab
plus lapatinib before undergoing surgery. Lapatinib alone
had a similar percentage of pCR as trastuzumab (53.2% and
52.5%, respectively; P = 0.98). The dual HER2 blockade was
associated with a higher pCR (62%; 95% CI 54.3 to 68.8) as
compared to single-agent HER2 therapy but the difference
was not statistically significant (P = 0.095) [41].
In another randomized trial performed in the neo-
adjuvant setting (Neo ALTTO), patients were randomized
among lapatinib, trastuzumab or lapatinib plus trastuzu-
mab, all in combination with paclitaxel after six weeks of
targeted therapy alone. The pCR rate was significantly
higher in the group treated with dual inhibition (51.3%) as
compared to trastuzumab alone (29.5%) (a 21.1% differ-
ence; 95% CI 9.1 to 34.2; P = 0.0001). There was no signifi-
cant difference in pCR between the lapatinib and the
trastuzumab group [42].
First results from the phase III ALLTO trial comparing
one year of lapatinib alone, trastuzumab alone, their











Table 1 Summary of randomized trials testing new drugs in Her2-overexpressing breast cancers
Drugs Targets Study Identifier number Phase Setting Primary endpoint Therapy Results
Pertuzumab HER2/3 CLEOPATRA NCT00567190 Phase III MBC/locally recurent/
unresectable
PFS Trastuzumab + docetaxel +
pertuzumab
18.7 months HR 0.69; 95% CI 0.58-0.81;
P <0.001
in first line trastuzumab + docetaxel +
placebo
12.4 months
NEOSPHERE NCT00545688 Phase II Neo adjuvant pCR Trastuzumab + docetaxel 29.0%
Trastuzumab + pertuzumab +
docetaxel
45.8% P = 0.0141
Pertuzumab + docetaxel 24.0%
Trastuzumab + pertuzumab 16.8%
T-DM1 HER2 EMILIA NCT00829166 Phase III MBC PFS T-DM1 9.6 months HR 0.65; 95% CI 0.55-0.77;
P <0.001
Lapatinib + Capecitabine 6.4 months
TH3RESA NCT01419197 Phase III MBC (in third line) T-DM1 6.2 months HR 0.528; 95% CI 0.422-0.661;
P <0.0001
Physician’s choice treatment 3.3 months
Lapatinib HER1/HER2 EGF104900 NCT00320385 Phase III MBC trastuzumab
resistant
PFS Lapatinib + trastuzumab
Lapatinib
11.1 months HR 0.74; 95% CI 0.58-0.94;
P = 0.011
8.1 months
NSABP B-41 NCT00486668 Phase III Neo adjuvant pCR Paclitaxel + Trastuzumab 53.5%
Paclitaxel + Lapatinb 52.5%
Paclitaxel + Lapatinib +
Trastuzumab
62.0%
NeoALTTO NCT00553358 Phase III Neo adjuvant pCR Paclitaxel + Trastuzumab 29.5%
Paclitaxel + Lapatinb 24.7%
Paclitaxel + Lapatinib +
Trastuzumab
51.3% difference 21.1%; 95%
CI 9.1-34.2; P = 0.0001).
ALLTO NCT00490139 Phase III Adjuvant DFS Trastuzumab 86.0%
Trastuzumab + Lapatinib 88.0%
Sequential Trastuzumab/Lapatinib
Geyer and al. NCT00078572 Phase III Locally advanced/MBC TTP Capecitabine + Lapatinib
Capecitabine
8.4 months HR 0.57; 95% CI 0.44-0.77;
P <0.001
4.4 month
GeparQuinto NCT00567554 Phase III Neo adjuvant pCR Chemotherapy + Trastuzumab 30.3% OR 0 · 68; 95% CI 0.47-0.97;
P = 0 · 04




















Table 1 Summary of randomized trials testing new drugs in Her2-overexpressing breast cancers (Continued)





BETH NCT00625898 Phase III Adjuvant DFS Chemotherapy + Trastuzumab +
Bevacizumab Chemotherapy +
Trastuzumab
HR 1.00; 95% CI 0.79–1.26
Everolimus m TOR BOLERO-3 NCT01007942 Phase III Locally advanced/MBC PFS Trastuzumab + Vinorelbine +
Everolimus Trastuzumab +
Vinorelbine
30.4 weeks HR 0.78; 95% CI 0.65-0.96;
P = 0.0067
25.1 weeks
CI, confidence interval; DFS, disease free survival; HR, hazard ratio; MBC, metastatic breast cancer; mTOR, mammalian target of rapamycin; OR, odds ratio; pCR, pathological complete response; PFS, progression free
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[42]. According to a predefined statistical plan, there was
no statistically significant difference between dual target-
ing HER2 and trastuzumab (four years DFS: 88% versus
86%; HR 0.84; 97.5% CI 0.70 to 1.02; P = 0.048). Neverthe-
less, this lack of benefit could be related to the low number
of events.
Neratinib
Neratinib is an oral irreversible pan-HER inhibitor. Preclin-
ical data on breast cancer cell lines suggest that it could
overcome both primary and acquired trastuzumab resist-
ance in HER2 positive breast cancer cell lines [43].
Neratinib has shown antitumor activity among both
pretreated and trastuzumab naive patients. In a phase II
trial, the median PFS observed with neratinib was 22.3 weeks
among patients with prior trastuzumab treatment and
39.6 weeks with trastuzumab naive patients. Objective re-
sponse rates were 24% and 56%, respectively [44].
Neratinib single agent has been compared with the
association of lapatinib plus capecitabine. Both median
PFS (4.5 months) and OS (19.7 months) for neratinib
single agent were found to be numerically inferior to
that of the combination therapy, although not statisti-
cally significant (PFS 4.5 months versus 6.8 months; OS
19.7 months versus 23.6 months, P = 0.231 and P = 0.280,
respectively) [45].
Neratinib is currently developed in combination with
paclitaxel, vinorelbine, capecitabine and temsirolimus
[46-49]. The association of neratinib and capecitabine
has been studied in a phase I/II trial. The median PFS
was 40.3 weeks and the overall response rate was 57%
for patients with no prior lapatinib treatment [50]. An on-
going phase III study (NCT00915018) compares weekly
paclitaxel with either neratinib or trastuzumab as first-line
treatment for HER2-positive MBC.
The most common adverse event of this treatment is
diarrhea in more than 90% of the cases, and then neutro-
penia (50% of the cases) [46,48].
Vascular endothelial growth factor inhibitors
The vascular endothelial growth factor (VEGF) plays a key
role in progression of this cancer by promoting tumor
angiogenesis [51]. Bevacizumab is a humanized monoclo-
nal antibody which targets VEGF and inhibits VEGF sig-
naling pathways.
In the AVEREL study, the efficacy of bevacizumab was
evaluated in first line therapy for locally recurrent or
metastatic HER2 positive breast cancer. In this phase III
study, the HR for progression was 0.72 (95% CI 0.54 to
0.94; P = 0.0162). The median PFS was 16.8 months in
the bevacizumab arm versus 13.9 months [52].
Bevacizumab was also evaluated in HER2 positive,
early breast cancer (BETH trial). In this trial, patientswere randomly assigned to receive chemotherapy, tras-
tuzumab plus bevacizumab, or chemotherapy and tras-
tuzumab alone. No difference of efficacy was observed
between the two arms (DFS, HR 1.00; 95% CI 0.79 to
1.26) [53].
Other antiangiogenic agents that can target VEGFR,
such as multitargeted anti-angiogenic TKIs (sunitinib, so-
rafenib, vandetanib) have shown promising results [54].
Monoclonal antibodies: pertuzumab
Resistance to trastuzumab can be explained by signaling
through other HER dimerization [26]. Pertuzumab is an
anti-HER2 antibody that inhibits HER2/HER3 dimeriza-
tions [26,55] and, thus, can prevent these potential escape
pathways. Binding of trastuzumab and pertuzumab is not
mutually exclusive and their differing mechanisms of
action act complementarily to provide a more complete
blockade of HER2 signal transduction. The combination
treatment with trastuzumab and pertuzumab has shown
strongly enhanced antitumor activity in xenograft models
with reduction in the levels of HER proteins [56].
Cortes et al. have evaluated whether adding pertuzumab
to trastuzumab could reverse trastuzumab resistance. The
objective response rate and clinical benefit rate (CBR)
were 3.4% and 10.3% in patients who received pertuzumab
monotherapy after trastuzumab. At the opposite end,
objective response rates and CBR were 17.6% and 41.2%
in patients who received the combination after progression
on trastuzumab [57].
Based on these data, the efficacy of adding pertuzumab
to trastuzumab has been investigated.
In the CLEOPATRA study, patients were randomized
between placebo plus trastuzumab plus docetaxel or per-
tuzumab plus trastuzumab plus docetaxel. The median
PFS was 12.4 months in the placebo group versus
18.7 months in the pertuzumab group (HR 0.69; 95% CI
0.58 to 0.81; P <0.001). The pertuzumab arm was also
associated with an OS improvement. The median OS in
the placebo group was 37.6 months (95% CI 34.3 to NE
(not estimable)) and had been not reached in the pertuzu-
mab group (95% CI 42.4 to NE) (HR 0.66; 95% CI 0.52 to
0.84; P = 0.0008) [58,59].
The combination of chemotherapy with trastuzumab
and pertuzumab has also shown interesting results in
the neo-adjuvant setting.
The NeoSphere study (multicenter phase II study)
evaluated the efficacy of dual inhibition using pertuzu-
mab. Patients who received pertuzumab and trastuzu-
mab plus docetaxel had a significantly higher pCR rate
(45.8%; 95% CI 36.1 to 55.7) compared to patients treated
with trastuzumab and docetaxel (29%; 95% CI 20.6 to
38.5; P = 0.0141). Interestingly, pertuzumab and trastuzu-
mab without chemotherapy was associated with a 16.8%
pCR [14].
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in the neoadjuvant setting. This trial investigated the
efficacy of trastuzumab and pertuzumab with three cycles
of FEC (5-fluorouracil, epirubicine, cyclophosphamide)
then three cycles of docetaxel, or three FEC then three do-
cetaxel with the combination of trastuzumab and pertuzu-
mab or docetaxel plus carboplatin plus the combination
during six cycles. The primary endpoint was to assess the
cardiac safety. The pCR rates were quite similar in the
three arms (61.6%, 57%, and 66.2%, respectively) [60].
In the early stage of breast cancer, the efficacy of per-
tuzumab is currently being investigated in the adjuvant
setting (APHINITY trial).
Antibody-drug conjugates: T-DM1
Trastuzumab emtansine (T-DM1) is an antibody-drug
conjugate and is composed of trastuzumab covalently
linked to maytansine, a cytotoxic agent [61].
The EMILIA study, a phase III registration trial com-
pared T-DM1 to lapatinib and capecitabine in patients
with HER2 positive advanced breast cancer previously
treated with trastuzumab and a taxane. The median PFS
was 9.6 months with T-DM1 versus 6.4 months with
lapatinib plus capecitabine (HR 0.65; 95% CI 0.55 to
0.77; P <0.001). The median OS at the second interim
analysis was 30.9 months in the T-DM1 arm versus
25.1 months in the lapatinib arm (HR 0.68; 95% CI 0.55
to 0.85; P <0.001) [62].
The phase III TH3RESA trial compared third line treat-
ment (including trastuzumab and lapatinib) of metastatic
or unresectable locally advanced or recurrent HER2
positive breast cancer with T-DM1 to the treatment of
the physician’s choice. T-DM1 treatment significantly
improved PFS compared with physician’s choice (median
PFS 6.2 months versus 3.3 months; HR 0.528; 95% CI
0.422 to 0.661; P <0.0001). Final overall survival analysis is
still awaited but interim analysis showed a trend favoring
T-DM1 with a lower incidence of grade 3 or worse ad-
verse events [63].
Another ongoing phase III trial, MARIANNE
(NCT01120184), compares single-agent T-DM1 to T-
DM1 combined with pertuzumab to trastuzumab plus a
taxane in first line treatment of metastatic breast cancer.
These studies will provide more information about the
indications of T-DM1 in the treatment algorithms for
HER2-positive disease.
mTOR inhibitors/PI3K inhibitors
The mammalian target of rapamycin (mTOR) is a serine-
threonine protein kinase that mediates mRNA translation
and protein synthesis. Activation of this pathway is known
as a mechanism of trastuzumab resistance [29,64]. Pre-
clinical studies have suggested that mTOR targeting could
reverse resistance to trastuzumab [65].In a phase I/II study, patients with HER2-positive
metastatic breast cancer received trastuzumab combined
with everolimus, after resistance to trastuzumab. Fifteen
percent of patients had a partial response and 19% had a
long stable disease (≥6 months). The clinical benefit rate
was 34% [66].
A phase II study evaluated the efficacy of everolimus
combined with trastuzumab and paclitaxel in patients
who were resistant to trastuzumab and taxane therapy.
The median PFS was 5.5 months and the median OS was
18.1 months [67]. This combination is currently being
evaluated in the BOLERO-1 trial.
The BOLERO-3 study compared the combination of
everolimus, trastuzumab plus vinorelbine to trastuzumab
and vinorelbine. The association of the mTOR inhibitor
with vinorelbine significantly improved PFS (30.4 weeks in
the everolimus arm versus 25.1 weeks in the placebo arm;
HR 0.78; 95% CI 0.65 to 0.96; P = 0.0067). In this study,
several biomarkers (PTEN, PIK3CA and pS6) were ana-
lyzed to find some subpopulation for whom the benefit of
everolimus was higher. Patients with a low PTEN and
high pS6 level seemed to derive more benefit from
addition of everolimus. Median PFS gain was 12 weeks for
the high pS6 level subgroup (HR 0.48; 95% CI 0.24 to
0.96) and 18 weeks for the low PTEN subgroup (HR 0.41;
95% CI 0.20 to 0.82). Unfortunately, there was no marker-
treatment interaction with PIK3CA mutation. These prom-
ising results deserve additional research.
Building on these results, the combination between
trastuzumab and BKM120, an oral pan-class 1 PI3K in-
hibitor, has been developed. It inhibits this signaling
pathway thanks to an ATP-competitive action. Several
objective responses were observed in a phase I study
[68], and this combination is currently being investi-
gated in a randomized trial in the neoadjuvant setting
(neoPHOEBE trial).
HSP90 inhibitors
Heat shock protein 90 (HSP90) is a chaperone which
stabilizes oncogenic proteins. Inhibition of HSP90 leads
to the degradation of these proteins involved in cancer
biology [69]. HSP90 inhibitors are currently being devel-
oped in ALK-translocated lung cancer, myeloma and
gastrointestinal stromal tumor (GIST). In HER2 positive
breast cancer, HSP90 inhibitors have shown antitumor
activity when combined with trastuzumab [70].
17-Demethoxygeldanamycin (17-AAG) inhibits the ac-
tivity of HSP90, thereby inducing the degradation of
many oncogenic proteins. In a phase II study, 17-AAG
(tanespimycin) was given in combination with trastuzu-
mab in patients who previously failed to trastuzumab. The
overall response rate (ORR) was 22%, the CBR was 59%,
the median PFS was six months and the median OS was
seventeen months [71].
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with trastuzumab showed modest clinical activity, but it
is possible that under-dosing limited efficacy [72]. Other
studies employing higher doses are ongoing.
These findings are promising and other studies are
expected to develop these new targeted therapies.
Blockade of PD-1/PD-L1 immune checkpoint
Programmed death 1 (PD-1) is a co-inhibitory receptor
and acts as a negative regulator of the immune system.
It is overexpressed on tumor-infiltrating lymphocytes
(TIL). The PD-1 ligand, PD-L1, is expressed by multiple
carcinoma, including breast cancers. This suggests that
the PD-1/PD-L1 signaling pathway could be a candidate
target in breast and other cancers.
T cell infiltration is predictive for the efficacy of tras-
tuzumab [73-76]. Biomarker studies have shown that
PD-1+ TILs are associated with poor prognosis in HER2
positive breast cancer [77,78] and preliminary data also
suggest a relationship between PD-L1 expression on
tumor cells and objective response to anti PD-1 therapy
[79]. The effects of anti-PD-1 and anti-PD-L1 antibodies
have been investigated in phase I trials in various cancer
types and have shown encouraging responses (response
rate 6 to 28% and stabilized disease rate 12% to 41%)
[80,81].
Preclinical studies have shown a synergism between
trastuzumab and anti-PD1 antibodies [82].
Other monoclonal antibody (mAb)-based therapies are
being investigated including anti CD73. Pre-clinical data
have suggested that it can delay tumor growth and inhibit
the development of metastases [83].
Conclusions
Although trastuzumab remains the standard treatment
in patients with HER2 overexpressing breast cancer in
neoadjuvant, adjuvant and metastatic settings, the pres-
ence of acquired and de novo resistance is a serious con-
cern. The understanding of resistance mechanisms could
allow developing strategies to prevent or overcome this
resistance. The development of novel targeted therapies
has changed the practices in metastatic settings.
New standards of care include trastuzumab plus pertu-
zumab plus docetaxel in first line treatment and TDM-1
for trastuzumab-resistant patients. In early breast cancer,
dual HER2 blockade has shown promising results in the
neoadjuvant setting. This strategy is being evaluated in
the adjuvant setting in several randomized trials.
Since several different targets are under investigation,
there is a need to identify predictive biomarkers to
optimize combination strategies for suitable patients.
Loss of PTEN and a high level of pS6 could facilitate the
selection of appropriate patients who can benefit from
personalized targeted therapy.Abbreviations
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